A Novel Gene Signature Associated with Inflammatory Responses and Immune Status Assists in Prognosis and Intervention for Patients with HCC

References

• El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132(7):2557–2576. doi:10.1053/j.gastro.2007.04.061
   PubMed Web of Science ®Google Scholar
• Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (Concord-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):1023–1075. doi:10.1016/S0140-6736(17)33326-3
   PubMed Web of Science ®Google Scholar
• Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357(9255):539–545. doi:10.1016/S0140-6736(00)04046-0
   PubMed Web of Science ®Google Scholar
• Boege Y, Malehmir M, Healy ME, et al. A dual role of caspase-8 in triggering and sensing proliferation-associated DNA damage, a key determinant of liver cancer development. Cancer Cell. 2017;32(3):342–359. doi:10.1016/j.ccell.2017.08.010
   PubMed Web of Science ®Google Scholar
• Donne R, Saroul-Ainama M, Cordier P, et al. Replication stress triggered by nucleotide pool imbalance drives DNA damage and cGAS-STING pathway activation in NAFLD. Dev Cell. 2022;57(14):1728–1741. doi:10.1016/j.devcel.2022.06.003
   PubMed Web of Science ®Google Scholar
• Lu G, Tian S, Sun Y, et al. NEK9, a novel effector of IL-6/STAT3, regulates metastasis of gastric cancer by targeting ARHGEF2 phosphorylation. Theranostics. 2021;11(5):2460–2474. doi:10.7150/thno.53169
   PubMed Web of Science ®Google Scholar
• Li T, Guo H, Zhao X, et al. Gastric cancer cell proliferation and survival is enabled by a cyclophilin B/STAT3/miR-520d-5p signaling feedback loop. Cancer Res. 2017;77(5):1227–1240. doi:10.1158/0008-5472.CAN-16-0357
   PubMed Web of Science ®Google Scholar
• Bu P, Wang L, Chen KY, et al. A miR-34a-numb feedforward loop triggered by inflammation regulates asymmetric stem cell division in intestine and colon cancer. Cell Stem Cell. 2016;18(2):189–202. doi:10.1016/j.stem.2016.01.006
   PubMed Web of Science ®Google Scholar
• Shinkawa H, Nakai T, Tamori A, et al. Hepatocellular carcinoma (HCC) recurring 10 years after clearance of hepatitis B surface antigen and 20 years after resection of hepatitis B virus-related HCC. Int J Clin Oncol. 2008;13(6):562–566. doi:10.1007/s10147-008-0785-z
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. doi:10.1016/j.cell.2011.02.013
   PubMed Web of Science ®Google Scholar
• Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31–46. doi:10.1158/2159-8290.CD-21-1059
   PubMed Web of Science ®Google Scholar
• Zhao H, Wu L, Yan G, et al. Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduct Target Ther. 2021;6(1):263. doi:10.1038/s41392-021-00658-5
   PubMed Web of Science ®Google Scholar
• Sperandio RC, Pestana RC, Miyamura BV, Kaseb AO. Hepatocellular carcinoma immunotherapy. Annu Rev Med. 2022;73:267–278. doi:10.1146/annurev-med-042220-021121
   PubMed Web of Science ®Google Scholar
• Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681–693. doi:10.1016/j.jhep.2021.11.018
   PubMed Web of Science ®Google Scholar
• Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894–1905. doi:10.1056/NEJMoa1915745
   PubMed Web of Science ®Google Scholar
• Zongyi Y, Xiaowu L. Immunotherapy for hepatocellular carcinoma. Cancer Lett. 2020;470:8–17. doi:10.1016/j.canlet.2019.12.002
   PubMed Web of Science ®Google Scholar
• Ruiz DGM, Bresnahan E, Molina-Sanchez P, et al. beta-catenin activation promotes immune escape and resistance to anti-PD-1 therapy in hepatocellular carcinoma. Cancer Discov. 2019;9(8):1124–1141. doi:10.1158/2159-8290.CD-19-0074
   PubMed Web of Science ®Google Scholar
• Yau T, Park JW, Finn RS, et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, Phase 3 trial. Lancet Oncol. 2022;23(1):77–90. doi:10.1016/S1470-2045(21)00604-5
   PubMed Web of Science ®Google Scholar
• Simon N, Friedman J, Hastie T, Tibshirani R. Regularization paths for cox’s proportional hazards model via coordinate descent. J Stat Softw. 2011;39(5):1–13. doi:10.18637/jss.v039.i05
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang Z, Shao C, et al. Melatonin may suppress lung adenocarcinoma progression via regulation of the circular noncoding RNA hsa_circ_0017109/miR-135b-3p/TOX3 axis. J Pineal Res. 2022;73(2):e12813. doi:10.1111/jpi.12813
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhang X, Zhang J, Tan J, Li J, Song Z. Development and validation of a combined ferroptosis and immune prognostic classifier for hepatocellular carcinoma. Front Cell Dev Biol. 2020;8:596679. doi:10.3389/fcell.2020.596679
   PubMed Web of Science ®Google Scholar
• Malta TM, Sokolov A, Gentles AJ, et al. Machine learning identifies stemness features associated with oncogenic dedifferentiation. Cell. 2018;173(2):338–354. doi:10.1016/j.cell.2018.03.034
   PubMed Web of Science ®Google Scholar
• Cheng X, Chen JZ, Guo YB. 肝癌分子靶向药对免疫系统的调节作用 [Regulatory effect of molecular targeted drugs on the immune system for liver cancer]. Zhonghua Gan Zang Bing Za Zhi. Chinese. 2021;29(10):1031–1034. doi:10.3760/cma.j.cn501113-20191006-00363
   PubMedGoogle Scholar
• Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol. 2001;2(9):533–543. doi:10.1016/S1470-2045(01)00486-7
   PubMed Web of Science ®Google Scholar
• Moon AM, Singal AG, Tapper EB. Contemporary epidemiology of chronic liver disease and cirrhosis. Clin Gastroenterol Hepatol. 2020;18(12):2650–2666. doi:10.1016/j.cgh.2019.07.060
   PubMed Web of Science ®Google Scholar
• Karki R, Kanneganti T. Diverging inflammasome signals in tumorigenesis and potential targeting. Nature Rev Cancer. 2019;19(4):197–214. doi:10.1038/s41568-019-0123-y
   PubMed Web of Science ®Google Scholar
• de Bono JS, Guo C, Gurel B, et al. Prostate carcinogenesis: inflammatory storms. Nature Rev Cancer. 2020;20(8):455–469. doi:10.1038/s41568-020-0267-9
   PubMed Web of Science ®Google Scholar
• Masson-Lecomte A, López De Maturana E, Goddard ME, et al. Inflammatory-related genetic variants in non–muscle-invasive bladder cancer prognosis: a multimarker bayesian assessment. Cancer Epidemiol Biomark Prevent. 2016;25(7):1144–1150. doi:10.1158/1055-9965.EPI-15-0894
   PubMed Web of Science ®Google Scholar
• Zhai W, Duan F, Chen S, et al. A novel inflammatory-related gene signature based model for risk stratification and prognosis prediction in lung adenocarcinoma. Front Genet. 2022;12:798131.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Schetter AJ, Yang GB, et al. microRNA and inflammatory gene expression as prognostic marker for overall survival in esophageal squamous cell carcinoma. Int J Cancer. 2013;132(12):2901–2909. doi:10.1002/ijc.27954
   PubMed Web of Science ®Google Scholar
• Wang Y, Yang Y, Zhao Z, et al. A new nomogram model for prognosis of hepatocellular carcinoma based on novel gene signature that regulates cross-talk between immune and tumor cells. Bmc Cancer. 2022;22(1):1–8.
   PubMed Web of Science ®Google Scholar
• Sia D, Jiao Y, Martinez-Quetglas I, et al. Identification of an immune-specific class of hepatocellular carcinoma, based on molecular features. Gastroenterology. 2017;153(3):812–826. doi:10.1053/j.gastro.2017.06.007
   PubMed Web of Science ®Google Scholar
• Snell LM, McGaha TL, Brooks DG. Type I interferon in chronic virus infection and cancer. Trends Immunol. 2017;38(8):542–557. doi:10.1016/j.it.2017.05.005
   PubMed Web of Science ®Google Scholar
• Morgan MR, Byron A, Humphries MJ, Bass MD. Giving off mixed signals-Distinct functions of α5 β1 and αv β3 integrins in regulating cell behaviour. Iubmb Life. 2009;61(7):731–738. doi:10.1002/iub.200
   PubMed Web of Science ®Google Scholar
• Ren J, Yang Y, Li C, et al. A novel prognostic model of early-stage lung adenocarcinoma integrating methylation and immune biomarkers. Front Genet. 2021;11. doi:10.3389/fgene.2020.634634
   Web of Science ®Google Scholar
• Lei Y, Yan W, Lin Z, Liu J, Tian D, Han P. Comprehensive analysis of partial epithelial mesenchymal transition‐related genes in hepatocellular carcinoma. J Cell Mol Med. 2021;25(1):448–462. doi:10.1111/jcmm.16099
   PubMed Web of Science ®Google Scholar
• Sterchi EE, Stocker W, Bond JS. Meprins, membrane-bound and secreted astacin metalloproteinases. Mol Aspects Med. 2008;29(5):309–328. doi:10.1016/j.mam.2008.08.002
   PubMed Web of Science ®Google Scholar
• OuYang H, Xu J, Luo J, et al. MEP1A contributes to tumor progression and predicts poor clinical outcome in human hepatocellular carcinoma. Hepatology. 2016;63(4):1227–1239. doi:10.1002/hep.28397
   PubMed Web of Science ®Google Scholar
• Asif A, Khalid M, Manzoor S, Ahmad H, Rehman AU. Role of purinergic receptors in hepatobiliary carcinoma in Pakistani population: an approach towards proinflammatory role of P2X4 and P2X7 receptors. Purinerg Signal. 2019;15(3):367–374. doi:10.1007/s11302-019-09675-0
   PubMed Web of Science ®Google Scholar
• Mo Z, Cao Z, Luo S, Chen Y, Zhang S. Novel molecular subtypes associated with 5mC methylation and their role in hepatocellular carcinoma immunotherapy. Front Mol Biosci. 2020;7. doi:10.3389/fmolb.2020.562441
   PubMed Web of Science ®Google Scholar
• Huang H, Zhou P, Wei J, et al. In vivo CRISPR screening reveals nutrient signaling processes underpinning CD8+ T cell fate decisions. Cell. 2021;184(5):1245–1261. doi:10.1016/j.cell.2021.02.021
   PubMed Web of Science ®Google Scholar
• Ling F, Zhang H, Sun Y, et al. AnnexinA7 promotes epithelial-mesenchymal transition by interacting with Sorcin and contributes to aggressiveness in hepatocellular carcinoma. Cell Death Dis. 2021;12(11):1018. doi:10.1038/s41419-021-04287-2
   PubMed Web of Science ®Google Scholar
• Finn RS, Ikeda M, Zhu AX, et al. Phase ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J Clin Oncol. 2020;38(26):2960–2970. doi:10.1200/JCO.20.00808
   PubMed Web of Science ®Google Scholar
• Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521–2532. doi:10.1056/NEJMoa1503093
   PubMed Web of Science ®Google Scholar
• Powles T, Eder JP, Fine GD, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014;515(7528):558–562. doi:10.1038/nature13904
   PubMed Web of Science ®Google Scholar
• Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol. 2015;26(12):2375–2391. doi:10.1093/annonc/mdv383
   PubMed Web of Science ®Google Scholar
• Donne R, Lujambio A. The liver cancer immune microenvironment: therapeutic implications for hepatocellular carcinoma. Hepatology. 2022. doi:10.1002/hep.32740
   Web of Science ®Google Scholar
• Chen R, Ganesan A, Okoye I, et al. Targeting B7‐1 in immunotherapy. Med Res Rev. 2020;40(2):654–682. doi:10.1002/med.21632
   PubMed Web of Science ®Google Scholar
• Lee MS, Ryoo B, Hsu C, et al. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. Lancet Oncol. 2020;21(6):808–820. doi:10.1016/S1470-2045(20)30156-X
   PubMed Web of Science ®Google Scholar
• Iitaka Y, Nakamura H, Nakatani T, et al. Chemistry of bleomycin. XX. The X-ray structure determination of P-3A Cu(II)-complex a biosynthetic intermediate of bleomycin. J Antibiot. 1978;31(10):1070–1072. doi:10.7164/antibiotics.31.1070
   PubMed Web of Science ®Google Scholar
• Cejka J, Kratochvil B, Cisarova I, Jegorov A. Simvastatin. Acta Crystallogr C. 2003;59(Pt 8):o428–o430. doi:10.1107/S0108270103012514
   PubMedGoogle Scholar
• Sarkar A. Cukrowski I. Tris(dicyclohexylammonium) hydrogen [1-hydroxy-2-(1H -imidazol-1-yl)-1-phosphonatoethane]phosphonate ethanol monosolvate monohydrate. Acta Crystallogr Sect E Struct Rep Online. 2011;67(11):o2980. doi:10.1107/S1600536811042206
   PubMedGoogle Scholar
• Hay J, Shahzeidi S, Laurent G. Mechanisms of bleomycin-induced lung damage. Arch Toxicol. 1991;65(2):81–94. doi:10.1007/BF02034932
   PubMed Web of Science ®Google Scholar
• Seitz SJ, Schleithoff ES, Koch A, et al. Chemotherapy-induced apoptosis in hepatocellular carcinoma involves the p53 family and is mediated via the extrinsic and the intrinsic pathway. Int J Cancer. 2010;126(9):2049–2066. doi:10.1002/ijc.24861
   PubMed Web of Science ®Google Scholar
• Pose E, Trebicka J, Mookerjee RP, Angeli P, Gines P. Statins: old drugs as new therapy for liver diseases? J Hepatol. 2019;70(1):194–202. doi:10.1016/j.jhep.2018.07.019
   PubMed Web of Science ®Google Scholar
• Feng J, Dai W, Mao Y, et al. Simvastatin re-sensitizes hepatocellular carcinoma cells to sorafenib by inhibiting HIF-1α/PPAR-γ/PKM2-mediated glycolysis. J Exp Clin Canc Res. 2020;39(1). doi:10.1186/s13046-020-1528-x
   Web of Science ®Google Scholar
• Honda Y, Aikata H, Honda F, et al. Clinical outcome and prognostic factors in hepatocellular carcinoma patients with bone metastases medicated with zoledronic acid. Hepatol Res. 2017;47(10):1053–1060. doi:10.1111/hepr.12844
   PubMed Web of Science ®Google Scholar